SCOTTSDALE, Ariz., April 12 /PRNewswire-FirstCall/ -- Research and development biotechnology company ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBO) , has named United States Air Force Nurse Corps Colonel Kerrie G. Lindberg (Ret.) to its recently established Bioterrorism Preparedness Advisory Board. Lindberg is a decorated Air Force officer, author, and recent retiree as Director of the Defense Institute for Medical Operations (DIMO), Brooks City-Base, TX.
The U.S. Food and Drug Administration’s (FDA) Division of Counter Terrorism (DCT) has requested that ImmuneRegen form the board to develop an emergency deployment plan for ImmuneRegen’s proprietary compound, Radilex(TM). Having undergone its seventh stage of testing, Radilex is a treatment currently in development to counteract the effects of lethal radiation exposure, anthrax or ricin poisoning, as well as similar inhalants.
“Colonel Lindberg is a substantial asset to our board of advisors and shares ImmuneRegen’s sense of urgency in developing a plan of prevention and protection from terrorist attacks,” said Michael Wilhelm, ImmuneRegen’s CEO. “With an extensive and decorated military and medical background, her counsel will be crucial in completing our mission to massively deploy Radilex(TM) as well as other countermeasures in case of a national bioterrorism disaster.”
Colonel Lindberg will be charged, along with her fellow board members, with developing a plan to disseminate the proprietary and potentially life-saving Radilex in the event of a biological or nuclear disaster. In this respect, Lindberg will be assisting Dr. Mark Witten, Advisory Board Chairman and ImmuneRegen BioSciences Chief Scientific Officer and Founder. Other members of the Bioterrorism Preparedness Advisory Board include Dr. William E. Hoehn, a legislative and executive veteran of the federal government and a researcher and think tank executive; Michael Caridi, a security industry entrepreneur and major real estate developer; and the Director to the Office of Homeland Security for the Texas A&M University System Health Science Center, Dr. Paul Carlton.
Lindberg earned a Master of Science in Health Systems Management in 1982 from Chapman College, an Air Force Institute of Technology (AFIT) Master of Science in Nursing from the University of New Mexico in 1992, and a Master of Science in Strategic Studies from Air University in 2000. She completed Squadron Officer School by correspondence in 1981 and in residence in 1985; Air Command and Staff College by seminar in 1984; and Air War College by seminar in 1995 and in residence in 1999.
As Director of DIMO, Lindberg directed, coordinated, and effected the merger of Air Force Institute for Global Health and Navy Defense Healthcare Management Institute, forming DIMO. There, her responsibilities included:
* Spearheading strategic planning; * Developing 15 international medical training programs; * Enhancing humanitarian/civil assistance and disaster/trauma response; * Orchestrating program/budget development, implementation, and execution; * Improving expeditionary medical field operations in conjunction with coalition military medical teams/host nation civilian authorities; * Collaborating with the DoS, DoD; Air Force, Army, and Navy; and civilian agencies; * Briefing senior leaders on DIMO accomplishments; * Moving DIMO as an entity under the Defense Security Cooperation Agency; * Managing a $2M budget.
Lindberg is certified in Nursing Administration, Advanced, by the American Nurses Association. She co-authored “The Costing Out of Operational Expenses Between the Veterans Administration and the Air Force at the New Mexico Regional Federal Medical Center”, in Military Medicine, November, 1992; and “A Global Engagement Enhancer: The International Health Specialist,” in Air & Space Power Journal, Fall 2002.
Military awards and decorations include the Legion of Merit Medal with one device, the Meritorious Service Medal with three devices, the Air Force Commendation Medal with one device, the Outstanding Unit Award with eight devices, the National Defense Service Medal with one device, the Military Outstanding Volunteer Service Medal with three devices, and the Small Arms Expert Marksmanship Ribbon. She was selected Junior Officer of the Quarter for hospital and base, Torrejon AB, Spain, in 1985; received the PACAF Medical Services Excellence Award in 1990; and was selected AFMC Field Grade Nurse of the Year in 1993.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc. is a biotechnology company engaged in the research and development of applications utilizing modified substance P, a naturally occurring immunomodulator. The company’s product, Homspera(TM), is derived from homeostatic substance P. The ongoing focus of ImmuneRegen BioSciences has been the continuing development of Homspera for various applications including the improvement of pulmonary function and the stimulation of the human immune system. The Homspera compound is also being developed as a therapeutic treatment in several other applications including radiation sickness (Radilex(TM)) and viral infection/biological warfare scenarios (Viprovex(TM)). For more information, please visit the company’s website at http://www.immuneregen.com/.
About Radilex(TM)
Radilex is a treatment currently in development for the negative effects of radiation, anthrax, ricin poisoning and other poisonous inhalants. Testing has shown a significant survival rate of radiation exposure at a 7.75 gray level, which is a lethal dosage. Radilex was derived from discoveries made during research funded by the Air Force Office of Scientific Research in the early 1990s. During this research, Dr. Mark Witten and his associates observed that exposure to jet fuels resulted in pathological changes in the lungs and immune systems of those exposed. It was also observed that such exposure resulted in depletion of substance P from the lungs. These studies further showed that the administration of substance P might help prevent and reverse the effects of jet fuel exposure in the lungs, as well as protect and regenerate the immune system.
Statements about the Company’s future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company’s actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research collaborations, clinical trials and product development programs, the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Company’s periodic report on Form 10-Q for the three months ended September 30, 2004 as filed with the Securities and Exchange Commission.
For further information, please contact: Jason Grimley of Spelling Communications, +1-310-477-9500, or fax, +1-310-477-9530, jgrimley@spellcom.com, for IR BioSciences Holdings, Inc.
IR BioSciences Holdings, Inc.
CONTACT: Jason Grimley of Spelling Communications, +1-310-477-9500, orfax, +1-310-477-9530, jgrimley@spellcom.com, for IR BioSciences Holdings,Inc.
Web site: http://www.immuneregen.com/
